试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-11
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
编号:NCT03136406登记状态:提前终止企业 / 申办者:ImmunityBio, Inc.
药物 / 成分:Cyclophosphamide、Oxaliplatin、Capecitabine、5-Fluorouracil
登记的停止原因(原文):Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-11
Epacadostat and Pembrolizumab in Patients With GIST
编号:NCT03291054登记状态:提前终止企业 / 申办者:Columbia University
药物 / 成分:Pembrolizumab、Epacadostat
登记的停止原因(原文):Study ended prematurely at the request of the funding sponsor.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-11
Vital Capacity in Ultrasound Guided Serratus Plane Block in ED Patients With Multiple Rib Fractures
编号:NCT04530149登记状态:提前终止企业 / 申办者:Antonios Likourezos
药物 / 成分:Acetaminophen、Bupivacain、Saline
登记的停止原因(原文):The original PI left the institution; COVID interrupted the study; difficult enrolling patients.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-11
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat
编号:NCT04981717登记状态:提前终止企业 / 申办者:Regeneron Pharmaceuticals
药物 / 成分:REGN1908-1909、Matching Placebo
登记的停止原因(原文):Lack of efficacy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-11
Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation
编号:NCT05435846登记状态:提前终止企业 / 申办者:Collin Blakely
药物 / 成分:Capmatinib、Trametinib
登记的停止原因(原文):slow accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-10
L-citrulline and Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia
编号:NCT03542812登记状态:提前终止企业 / 申办者:University of Utah
药物 / 成分:L-Citrulline
登记的停止原因(原文):The study stopped enrollment prior to the initially projected 18 subjects per phase due to lack of funding to continue to recertify the drug and because an adequate number of subjects were enrolled for each phase to analyze pharmacokinetics.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-10
Angiotensin 1-7 in Obesity Hypertension
编号:NCT03604289登记状态:提前终止企业 / 申办者:Amy Arnold
药物 / 成分:Angiotensin-(1-7)、Saline
登记的停止原因(原文):Funding terminated
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-10
Trial for Treatment Refractory Trigeminal Neuralgia
编号:NCT03941834登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:Rimegepant、Placebo
登记的停止原因(原文):Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-07
Processed Amniotic Fluid (pAF) for the Treatment of Chronic Wounds
编号:NCT04438174登记状态:提前终止企业 / 申办者:University of Utah
药物 / 成分:Processed Amniotic Fluid、Standard of Care Wound Treatment Regimen
登记的停止原因(原文):Enrollment was halted prematurely after enrolling one participant due to difficulty finding eligible participants.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-07
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
编号:NCT06022224登记状态:提前终止企业 / 申办者:ImmunityBio, Inc.
药物 / 成分:hAd5-S-Fusion+N-ETSD、Placebo (0.9% (w/v) saline)
登记的停止原因(原文):There were no participants enrolled into Phase 3 portion of the study because the study was prematurely terminated.
查看官方原始记录 ↗